Form 4: Korro Bio CFO Exercises and Sells Shares Under 10b5-1 Plan

Korro Bio's Chief Financial Officer, Vineet Agarwal, executed a pre-planned sale of 800 shares of common stock and exercised a stock option for 800 shares at a price of $11.68 per share.

Summary

• Vineet Agarwal, the Chief Financial Officer of Korro Bio, Inc., engaged in transactions involving the company's stock on November 11, 2024.
• Mr. Agarwal exercised a stock option to acquire 800 shares of common stock at a price of $11.68 per share.
• Simultaneously, Mr. Agarwal sold 800 shares of common stock at a price of $70 per share.
• These transactions were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on July 19, 2024.
• The stock options vest over time, with 25% vesting on May 11, 2022, and the remainder vesting in 36 equal monthly installments.

Sentiment

Score: 6

Explanation: The document reflects routine insider trading activity under a pre-planned 10b5-1 plan. While the sale of shares could be perceived negatively, the structured nature of the transactions mitigates this concern. The sentiment is neutral to slightly positive.

Positives

• The transactions were executed under a pre-planned 10b5-1 trading plan, indicating a structured approach to stock transactions.
• The sale of shares at $70 per share indicates a significant gain compared to the exercise price of $11.68.

Negatives

• The sale of shares by the CFO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react to insider selling, even if it is part of a pre-planned trading plan.
• Changes in the company's performance or market conditions could affect the value of the remaining stock options.

Industry Context

This is a routine filing related to insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to manage their stock transactions.
• The vesting schedule of the stock options is typical for employee equity compensation packages.
• The sale of shares by an executive is a normal occurrence and does not necessarily indicate a negative outlook for the company.

Stakeholder Impact

• Shareholders may react to the insider selling, although it is part of a pre-planned strategy.
• Employees may be interested in the details of the stock option vesting schedule.

Key Dates

Keywords

Korro Bio, insider trading, stock options, Rule 10b5-1, SEC Form 4, Vineet Agarwal, equity securities, beneficial ownership